1. The Clinical Impact of the Pretreatment Albumin to Fibrinogen Ratio in Esophageal Cancer Patients Who Receive Curative Treatment.
- Author
-
Aoyama T, Maezawa Y, Hashimoto I, Hara K, Kazama K, Komori K, Kato A, Otani K, Tamagawa A, Cho H, Morita J, Kawahara S, Tanabe M, Oshima T, Saito A, Yukawa N, and Rino Y
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Prognosis, Biomarkers, Tumor blood, Serum Albumin analysis, Neoplasm Staging, Neoplasm Recurrence, Local pathology, Aged, 80 and over, Adult, Esophageal Neoplasms blood, Esophageal Neoplasms surgery, Esophageal Neoplasms mortality, Esophageal Neoplasms pathology, Fibrinogen metabolism
- Abstract
Background/aim: The albumin to fibrinogen ratio (AFR) has been identified as a promising prognostic marker for some malignancies. The aim of the present study was to evaluate the clinical impact of AFR in esophageal cancer patients who received curative resection., Patients and Methods: The present study included 123 patients who underwent curative treatment for esophageal cancer between 2005 and 2020. The prognosis and clinicopathological parameters were compared between patients with high and low AFRs., Results: The overall survival (OS) stratified by each clinical factor was compared using the log-rank test, and a significant difference was observed when using a pretreatment AFR of 1.23. When comparing the patient backgrounds between the high-AFR (AFR ≥12.3) and low-AFR (AFR<12.3) groups, significant differences were noted in the pathological T status. The high-AFR group had significantly higher OS rates at 3 years (70.8%) and 5 years (59.3%) after surgery in comparison to the low-AFR group (46.6% and 37.4%, respectively). Univariate and multivariate analyses for OS showed that the AFR was a significant prognostic factor. In addition, when comparing the site of first recurrence, a marginally significant difference was noted in hematological recurrence., Conclusion: The AFR is a significant risk factor in patients with esophageal cancer, holding promise as a valuable prognostic factor., (Copyright © 2024, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF